In the Media

New York Times Style Magazine reporter Susan Dominus spotlights the “maximalist, category-defying work” of MIT Prof. Emerita Joan Jonas, who is being honored with a retrospective at the MoMA. “Perception is something that really is an important part of my thinking,” Jonas explains. “How does the audience perceive my work? How does my work change their perception?” Michael Rakowitz SMVisS ’98 notes that Jonas, “is a foundational and transformative figure not just in the realm of video and performance and feminist art but in art that moves away from anthropocentrism.”

TechCrunch reporter Haje Jan Kamps spotlights AgZen, an MIT startup that has developed a new tool that optimizes the use of pesticides to avoid over application. “The real winner in all of this may prove to be public health and the environment,” writes Jan Kamps. “By reducing foliar pesticide usage by 30% to 50%, AgZen’s technology might help mitigate [environmental] impacts, aligning with the critical need for improved spray efficiency highlighted in recent reports.”

BioBot - a public health research, data and analytics firm co-founded by Mariana Matus PhD '18 and Newsha Ghaeli PhD '17 - is using wastewater testing to provide insights into growing infection rates and diseases across the country, reports Soledad O’Brien for WCVB-TV.

Prof. Nathaniel Hendren and Prof. Justin Steil speak with New York Times reporter Jason DeParle about the difficulty in building affordable housing in opportunity-rich neighborhoods. “A lot has changed in American life over the past 50 years, but the hostility to affordable housing has remained surprisingly durable,” Steil explains. “Where you grow up matters a great deal for shaping your life outcomes,” Hendren adds.

Senior Lecturer Guadalupe Hayes-Mota writes for Forbes about the ways AI is reshaping drug development. “In the next three years, we can anticipate a more streamlined, efficient and cost-effective drug development process, ultimately leading to faster access to life-saving drugs for patients worldwide,” Hayes-Mota writes. “This is not just an evolution; it is a revolution in healthcare powered by the intelligence of machines.”

Prof. Charles Stewart III and Ben Adida PhD ’06 speak with Fast Company reporter Spenser Mestel about how to restore the public’s faith in voting technology. Adida discusses his work launching VotingWorks, a non-profit focused on building voting machines. VotingWorks is “unique among the legacy voting technology vendors," writes Mestel. “The group has disclosed everything, from its donors to the prices of its machines.”

Senior Research Scientist Lisa Barsotti speaks with MIT Technology Review reporter Sophia Chen about how she and her colleagues developed a new device that uses quantum squeezing to help the LIGO detectors identify more celestial events, such as black hole mergers and neutron star collisions. “With these latest squeezing innovations, installed last year, the collaboration expects to detect gravitational waves up to 65% more frequently than before,” Chen explains.

A new study by MIT researchers finds that an experimental Alzheimer’s treatment involving sound and light stimulation at a frequency of 40 Hz is associated with, “an increase in activity of the brain's own cleanup crew; the glymphatic system,” reports Pandora Dewan for Newsweek. The findings offer an, “exciting, non-invasive potential treatment option for patients with neurological disorders in the future,” Dewan notes.

MIT scientists have found that an experimental treatment for Alzheimer's disease involving sounds and flickering lights appears to “ramp up the brain’s waste disposal networks, which boosts the clearance of beta-amyloid and other toxic proteins that contribute to memory and concentration problems,” reports Clare Wilson for New Scientist. “Once we understand the mechanism, we can probably figure out how to further optimize this whole concept and improve the efficacy,” explains Prof. Li-Huei Tsai.

Prof. Feng Zhang has been named to STAT’s 2024 STATUS List, which highlights the leaders shaping the future of health and life sciences, reports Dialynn Dwyer for Boston.com. “Among the companies he’s co-founded is Editas Medicine, which as of late 2023 was now the official holder of patent rights to the CRISPR-Cas9 gene editing tool used in the sickle cell therapy Casgevy, and Aera Therapeutics, which in February 2023 raised $193 million in venture funding to develop protein nanoparticles as a way of delivering gene editing,” Dwyer writes.

Writing for The Hill, Prof. Christopher Knittel and graduate student Kailin Graham emphasize the importance of ensuring the transition away from fossil fuels is an equitable process that provides support for vulnerable workers. “If we’re serious about achieving a truly just transition, far more federal policy action is needed,” they write.

Los Angeles Times reporter Gustavo Arellano spotlights Democratic Senator Alex Padilla ’94 and his political career in California. Padilla “realized the only way to make things better for the Valley’s growing Latino community, in an era of anti-immigrant sentiment across California, was to elect politicians who looked like them,” writes Arellano.

Prof. Abhijit Banerjee shares advice with Nature reporter Helen Pearson for those in science careers looking to find “satisfaction from their work – and make a difference to the world.” Banerjee attributes “his own career to a series of happy accidents,” writes Pearson. Banerjee says, “a lot of it is accidents that make us who we are…sometimes we learn something about ourselves as a result of them.”

Former postdoc Leah Ellis speaks with GBH All Things Considered host Arun Rath about   Sublime Systems, an MIT startup she co-founded that aims to produce carbon-free cement to combat climate change. “Sublime Systems and this technology spun out of my postdoctoral work at MIT,” says Ellis. “My co-founder and I are both electric chemists, so we have experience with battery technologies and electrochemical systems. Our idea was thinking about how we might use renewable energy—which we know has become more abundant, inexpensive and available—to eliminate the CO2 emissions from cement.”

Researchers at MIT and elsewhere have developed a machine-learning model that can identify which drugs should not be taken together, reports Politico. “The researchers built a model to measure how intestinal tissue absorbed certain commonly used drugs,” they write. “They then trained a machine-learning algorithm based on their new data and existing drug databases, teaching the new algorithm to predict which drugs would interact with which transporter proteins.”